Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
received:
04
04
2023
accepted:
25
07
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is associated with increased secretion of apoB-containing lipoproteins and increased risk of coronary heart disease (CHD). ApoB-containing lipoproteins include low-density lipoproteins (LDLs) and triglyceride-rich lipoproteins (TRLs); and since both LDLs and TRLs are causally related to CHD, they may mediate a portion of the increased risk of atherosclerosis seen in people with NAFLD. In a cohort of 4161 middle aged men and women, we performed mediation analysis in order to quantify the mediating effect of apoB-containing lipoproteins in the relationship between liver fat and atherosclerosis-as measured by coronary artery calcium score (CACS). We found plasma apoB to mediate 17.6% (95% CI 11-24) of the association between liver fat and CACS. Plasma triglycerides and TRL-cholesterol (both proximate measures of TRL particles) mediated 22.3% (95% CI 11-34) and 21.6% (95% CI 10-33) of the association respectively; whereas LDL-cholesterol mediated 5.4% (95% CI 2.0-9.4). In multivariable models, the mediating effect of TRL-cholesterol and plasma triglycerides showed, again, a higher degree of mediation than LDL-cholesterol, corroborating the results seen in the univariable models. In summary, we find around 20% of the association between liver fat and CACS to be mediated by apoB-containing lipoproteins. In addition, we find that TRLs mediate the majority of this effect whereas LDLs mediate a smaller effect. These results explain part of the observed CAD-risk burden for people with NAFLD and further suggest that TRL-lowering may be particularly beneficial to mitigate NAFLD-associated coronary artery disease risk.
Identifiants
pubmed: 37580332
doi: 10.1038/s41598-023-39390-1
pii: 10.1038/s41598-023-39390-1
pmc: PMC10425432
doi:
Substances chimiques
Lipoproteins
0
Triglycerides
0
Cholesterol
97C5T2UQ7J
Apolipoproteins B
0
Cholesterol, LDL
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13217Informations de copyright
© 2023. Springer Nature Limited.
Références
Adiels, M. et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49(4), 755–765. https://doi.org/10.1007/s00125-005-0125-z (2006).
doi: 10.1007/s00125-005-0125-z
pubmed: 16463046
Borén, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 41(24), 2313–2330. https://doi.org/10.1093/eurheartj/ehz962 (2020).
doi: 10.1093/eurheartj/ehz962
pubmed: 32052833
pmcid: 7308544
Ginsberg, H. N. et al. Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society. Eur. Heart J. 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551 (2021).
doi: 10.1093/eurheartj/ehab551
pubmed: 34472586
pmcid: 8670783
Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6(11), 903–913. https://doi.org/10.1016/S2468-1253(21)00308-3 (2021).
doi: 10.1016/S2468-1253(21)00308-3
pubmed: 34555346
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J. Hepatol. 65(3), 589–600. https://doi.org/10.1016/j.jhep.2016.05.013 (2016).
doi: 10.1016/j.jhep.2016.05.013
pubmed: 27212244
Wu, S. et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci. Rep. 6(August), 1–14. https://doi.org/10.1038/srep33386 (2016).
doi: 10.1038/srep33386
Al Rifai, M. et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 239(2), 629–633. https://doi.org/10.1016/j.atherosclerosis.2015.02.011 (2015).
doi: 10.1016/j.atherosclerosis.2015.02.011
pubmed: 25683387
pmcid: 4406399
Gummesson, A. et al. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects. PLoS ONE 13(8), 1–16. https://doi.org/10.1371/journal.pone.0202666 (2018).
doi: 10.1371/journal.pone.0202666
Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38(32), 2459–2472. https://doi.org/10.1093/eurheartj/ehx144 (2017).
doi: 10.1093/eurheartj/ehx144
pubmed: 28444290
pmcid: 5837225
Wu, H. et al. The gut microbiota in prediabetes and diabetes: A population-based cross-sectional study. Cell Metab. 32(3), 379-390.e3. https://doi.org/10.1016/j.cmet.2020.06.011 (2020).
doi: 10.1016/j.cmet.2020.06.011
pubmed: 32652044
Bergström, G. et al. The Swedish CArdioPulmonary BioImage study: Objectives and design. J. Intern. Med. 278(6), 645–659. https://doi.org/10.1111/joim.12384 (2015).
doi: 10.1111/joim.12384
pubmed: 26096600
pmcid: 4744991
Kramer, H. et al. Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: Prospective comparison with MR spectroscopy. Am. J. Roentgenol. 208(1), 92–100. https://doi.org/10.2214/AJR.16.16565 (2017).
doi: 10.2214/AJR.16.16565
Kullberg, J. et al. Automated analysis of liver fat, muscle and adipose tissue distribution from CT suitable for large-scale studies. Sci. Rep. 7(1), 1–11. https://doi.org/10.1038/s41598-017-08925-8 (2017).
doi: 10.1038/s41598-017-08925-8
Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. Mediation: R package for causal mediation analysis. J. Stat. Softw. 59(5), 1–38. https://doi.org/10.18637/jss.v059.i05 (2014).
doi: 10.18637/jss.v059.i05
Parry, S. A. & Hodson, L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J. Investig. Med. 65(8), 1102–1115. https://doi.org/10.1136/jim-2017-000524 (2017).
doi: 10.1136/jim-2017-000524
pubmed: 28947639
pmcid: 5749316